Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06674863 | Addressing Health Literacy With a Tailored Survivorship Care Plan | recruiting | N/A | 150 | Emory UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) |
| recruiting |
| Phase 3 |
| 450 |
| Nuvalent Inc.INDUSTRY |
| 29 |
| Sep 30, 2026 |
| clinicaltrials |
| NCT06770582 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | recruiting | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06826014 | TREC@TAMU Cancer Prevention Registry and Repository | recruiting | — | 2,500 | Texas A&M UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06890273 | NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)(DUOLife) | recruiting | — | 150 | AstraZenecaINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | recruiting | Phase 1 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06917911 | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) | recruiting | Phase 2 | 162 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06918002 | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients(ElLen) | recruiting | Phase 3 | 824 | Intergroupe Francophone du MyelomeNETWORK | 2 | Sep 30, 2026 | clinicaltrials |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 65 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
| NCT07023887 | Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning(EXERT-BCHC) | recruiting | — | 15 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07061964 | Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | recruiting | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | recruiting | Phase 1 | 170 | ALX Oncology Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | recruiting | Phase 3 | 255 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07218250 | A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07231952 | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07328503 | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 32 | Sep 30, 2026 | clinicaltrials |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | recruiting | Phase 3 | 750 | Bristol-Myers SquibbINDUSTRY | 36 | Sep 30, 2026 | clinicaltrials |
| NCT07378670 | DEfeating PEnile CAncer-2(DEPECA-2) | recruiting | N/A | 80 | University Hospital TuebingenOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07410169 | Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy | recruiting | Phase 2 / Phase 3 | 160 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07437950 | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 126 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)(ALISCA-Lung2) | recruiting | Phase 2 | 50 | Puma Biotechnology, Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303) | recruiting | Phase 3 | 900 | Revolution Medicines, Inc.INDUSTRY | 12 | Sep 30, 2026 | clinicaltrials |
| NCT07509034 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease | recruiting | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07526675 | Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer(Bioblation) | recruiting | N/A | 30 | Benha UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07619534 | Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases | recruiting | — | 139 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07621471 | IL-15 Enhanced NK Cell Therapy for Solid Tumors | recruiting | Early Phase 1 | 12 | Genovn Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer(TARGET-D 202) | recruiting | Phase 2 | 105 | Verastem, Inc.INDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07686380 | IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07698314 | A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer(Myo-EXERTBC) | recruiting | N/A | 21 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | recruiting | Phase 3 | 436 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07740941 | NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | recruiting | Phase 2 | 55 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07782814 | An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool(DiTECT) | recruiting | — | 220 | Zedsen LimitedINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07835412 | A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways | recruiting | — | 5,000 | Beijing Tiantan HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07842835 | Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China(CLIMB) | recruiting | — | 400 | Xiaohui RenOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | recruiting | — | 40 | Beijing Municipal Administration of HospitalsOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848815 | Risk-Based Lung Cancer Detection in COPD Patients(ELUCID) | recruiting | N/A | 1,000 | Vejle HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848828 | Autonomic and Renal Contributions to Hypertension With ADT(ARCH) | recruiting | Phase 4 | 50 | Virginia Commonwealth UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848841 | Online Perioperative Education Program on Patient Satisfaction and Clinical Outcomes for Head and Neck Surgery | recruiting | N/A | 50 | Washington University School of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
Data updated 2 minutes agoSource updated Sep 30, 2026source: clinicaltrials